Note 2 - Selected Balance Sheet Data (Details Textual) $ in Thousands |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
|
Sep. 30, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Sep. 30, 2017
USD ($)
|
Sep. 30, 2016
USD ($)
|
Jun. 30, 2017
USD ($)
|
|
| Available-for-sale Securities | $ 50,300 | $ 50,300 | $ 66,100 | ||
| Payments to Acquire Available-for-sale Securities | $ 6,836 | ||||
| Number of Reporting Units | 3 | ||||
| Goodwill, Impairment Loss | $ 0 | ||||
| Other Assets, Noncurrent | 44,572 | 44,572 | 44,002 | ||
| Astute Medical, Inc. [Member] | |||||
| Payments to Acquire Investments | $ 40,000 | ||||
| Certificates Of Deposit [Member] | CHINA | |||||
| Payments to Acquire Available-for-sale Securities | 1,400 | ||||
| ChemoCentryx, Inc (CCXI) [Member] | |||||
| Available-for-sale Equity Securities, Amortized Cost Basis | 29,500 | 29,500 | $ 29,500 | ||
| Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member] | |||||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities | $ 2,100 | $ 2,100 | |||
| X | ||||||||||
- Definition This item represents the cost of equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments for other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. No definition available.
|
| X | ||||||||||
- Definition Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. No definition available.
|
| X | ||||||||||
- Definition Amount of noncurrent assets classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|